Mauna Kea Technologies

The Cellvizio® 100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries.

This marks the 16th U.S. FDA 510(k) clearance of the Cellvizio® p/nCLE platform.

This scientific publication, entitled "Intraoperative confocal laser endomicroscopy for real-time in vivo tissue characterization during surgical procedures", reports on outcomes of 21 consecutive patients that underwent laparoscopic surgery at the Institut Mutualiste Montsouris (IMM) in Paris, France, between 2014 and 2015.

“The lung has the highest rate of acute rejection of any transplanted organ,” said Cesar Keller, M.D., Lung Transplant Program, Mayo Clinic, Jacksonville, Florida and first author of the study. “However, the current standard of care, transbronchial biopsy, requires multiple samples to be obtained per biopsy and carries a high risk of serious adverse events including pneumothorax and/or pulmonary bleeding. Considering the relatively frequent need to monitor these patients for acute rejection, better and less invasive methods to assess acute rejection would significantly improve patient care and outcomes.”

Results from new clinical study that enrolled 172 patients at 8 non-academic centers in the United-States was presented at 2018 World Congress of Endoscopic Surgery hosted by SAGES and CAGS.

April 3, 2017 Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the presentation of data from the National French Registry on Cellvizio® procedures confirming the strong performance of confocal laser endomicroscopy (CLE)...